tropicamide has been researched along with Parkinson Disease in 3 studies
Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This proof-of-concept, pilot study aimed to explore the safety and anti-sialorrhea efficacy of single doses of intra-oral slow dissolving thin films containing tropicamide (NH004) or placebo." | 9.15 | A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. ( Carrosella, A; Gamzu, E; Lloret, SP; Merello, M; Nano, G, 2011) |
| "This proof-of-concept, pilot study aimed to explore the safety and anti-sialorrhea efficacy of single doses of intra-oral slow dissolving thin films containing tropicamide (NH004) or placebo." | 5.15 | A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. ( Carrosella, A; Gamzu, E; Lloret, SP; Merello, M; Nano, G, 2011) |
| "Diagnostic tests for Alzheimer's disease (AD) involving tropicamide blockade of cholinergic oculomotor functions were examined in AD patients (n=15), Parkinson's disease (PD) patients (n=15), and non-clinical control (NC) participants (n=15)." | 2.71 | Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. ( Galasko, D; Granholm, E; Morris, S; Rogers, E; Shults, C; Vukov, B, 2003) |
| " The advantages of NH004 include local bioavailability with low systemic exposure, rapid onset of action and, importantly, convenience of use for patients." | 2.52 | Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease. ( Farber, NM; Gamzu, ER; Perez-Lloret, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farber, NM | 1 |
| Perez-Lloret, S | 1 |
| Gamzu, ER | 1 |
| Lloret, SP | 1 |
| Nano, G | 1 |
| Carrosella, A | 1 |
| Gamzu, E | 1 |
| Merello, M | 1 |
| Granholm, E | 1 |
| Morris, S | 1 |
| Galasko, D | 1 |
| Shults, C | 1 |
| Rogers, E | 1 |
| Vukov, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients[NCT00761137] | Phase 2 | 19 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Saliva volume was measured at baseline and 75 minutes after treatment administration. Volumes were measured by using cotton rolls placed near each Stenton duct and below the tongue for 5 minutes; cotton rolls were centrifuged and the volume of saliva determined. (NCT00761137)
Timeframe: Before and 75 minutes after treatment administration
| Intervention | percentage change of saliva volume (Median) |
|---|---|
| Tropicamide - Placebo | -5 |
| Tropicamide - 0.3 mg | -27 |
| Tropicamide - 1 mg | -33 |
| Tropicamide 3 mg | -20 |
Saliva buccal assessment was evaluated by an VAS scale before, and 15, 30, 45, 60, 90, and 120 min after treatment administration. Subjects were asked to rate how much saliva they perceived in their buccal cavity on an unmarked 0 to 10 cm line, higher scores meaning greater perceived buccal saliva levels. (NCT00761137)
Timeframe: Before and 120 min after treatment administration
| Intervention | cm on VAS (Mean) |
|---|---|
| Tropicamide - Placebo | -0.55 |
| Tropicamide - 0.3 mg | -1.08 |
| Tropicamide - 1 mg | -1.53 |
| Tropicamide 3 mg | -0.81 |
1 review available for tropicamide and Parkinson Disease
| Article | Year |
|---|---|
Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease.
Topics: Animals; Drug Design; Drug Discovery; Humans; Muscarinic Antagonists; Parkinson Disease; Sialorrhea; | 2015 |
2 trials available for tropicamide and Parkinson Disease
| Article | Year |
|---|---|
A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients.
Topics: Administration, Oral; Analysis of Variance; Cross-Over Studies; Dose-Response Relationship, Drug; Do | 2011 |
Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease.
Topics: Aged; Alzheimer Disease; Female; Humans; Light; Male; Muscarinic Antagonists; Ophthalmic Solutions; | 2003 |